Selected News from Today's FirstWord

Genentech forms committee to review Roche's takeover bid
by Alison Fischer

Genentech announced that it formed a special committee to assess Roche's $43.7-billion bid to acquire the shares it does not already own in the biotechnology company. Genentech's board said it wouldn't recommend the deal, which it stated was both "unsolicited and unexpected," unless it received a favourable recommendation by the committee. Full story

• Bristol-Myers Squibb 2Q profit boosted on Plavix sales - (Ref. MarketWatch; Bloomberg; CNN Money; MSN Money; Yahoo!Finance; Bristol-Myers Squibb)
• Eli Lilly's second-quarter results helped by revenue for Cymbalta, Cialis - (Ref. Forbes; Bloomberg; CNN Money; MarketWatch; The Indianapolis Star; Yahoo!Finance; Eli Lilly)
• Gene mutation linked to myopathy in patients taking statins, study - (Ref. BBC News; Bloomberg; The Globe and Mail; The Star-Ledger; The Wall Street Journal; NEJM)
• Analysts comment on potential of Alzheimer's disease candidate bapineuzumab - (Ref. Bloomberg)
• FDA issues alert over GlaxoSmithKline's Ziagen - (Ref. Bloomberg; International Herald Tribune; The New York Times; FDA)

Also in the News

• Products:
• Catena,
• Fentora,
• Osteocel,
• Plavix,
• Prochymal,
• telavancin,
• XOMA 629

• Companies:
• Biogen Idec,
• BMS,
• Harvard,
• Momenta,
• Roche,
• Theravance,
• Zelos

• Markets:
• EU,
• India,
• US,
• World

Most Read Stories in the Past Week

• Vytorin does not meet main study goals in SEAS trial
• Roche bids for remaining stake in Genentech
• Teva to buy Barr
• Analysts comment on Roche's bid for Genentech
• GlaxoSmithKline reports 2Q results, announces new strategic priorities